Calcium Citrate 1000 mg + Vitamin D3 200 IU + Zinc 4 mg + Magnesium 100 mg Tablets is a multi-nutrient solid oral pharmaceutical product containing calcium citrate, vitamin D3, zinc and magnesium in a single standardized formulation system. The product is manufactured by controlled formulation design to deliver precise amounts of ingredients, robust and homogenous tablet characteristics and end-product quality.
The combination of minerals with vitamins necessitates choice of pharmaceutical-grade raw ingredients with compatible excipients. Each ingredient has different physical and chemical properties so formulation development activities are concentrated on compatibility, homogeneous blending, compression and stability. End-product tablets can be integrated into a broader pharmaceutical-orientated portfolio where rigorous standards of quality and presentation may be expected. Combination formulations like this can help diversify a PCD Pharma Franchise portfolio.
Four main ingredients are controlled at specified levels – calcium citrate 1000 mg, vitamin D3 200 IU, zinc 4 mg, and magnesium 100 mg – at each stage of manufacture. Each product at those levels needs to be dispensed in accurate quantities and released through robust manufacturing procedures.
Calcium citrate will be a significant mineral component by weight, shaping the physical composition of the powder blend. Zinc and magnesium, in smaller quantities, will require appropriate blending to ensure homogeneity throughout the finished blend.
Vitamin D3 is present at a relatively low level in comparison to the mineral ingredients and so will need appropriate blending to ensure uniform dispersion. Appropriate pharmaceutical excipients may be selected to enhance powder flow, binding, lubrication, compression and pharmaceutical integrity of the finished tablets.
Depending on the manufacturing methodology selected, excipients may include diluents, binders, disintegrants, lubricants, glidants and other functional excipients. An appropriate excipient system will be selected through a developed formulation strategy and compatibility testing.
The manufacturing process of calcium citrate 1000 mg + vitamin D3 200 IU + zinc 4 mg + magnesium 100 mg tablets begins with the controlled receipt and testing of incoming raw materials. Each ingredient is subject to stringent specifications and only released for the manufacturing process once proven to comply.
Dispensing accuracy is particularly important as ingredients are present at substantially different quantities – accurate dispensing within tight tolerances will be essential to preserve composition. Controlled weighing will maintain the desired composition of each finished batch.
Depending on the formulation design, processes such as sifting, pre-blending, geometric dilution, granulation, drying, additional blending, lubrication and compression may be utilized. The manufacturer will select a process that ensures rapid flow and an even distribution of all active ingredients.
As calcium citrate contributes a significant portion of total ingredient weight, process parameters such as powder flow and compressibility will be monitored for uniformity. Appropriate granulation or direct compression procedures may be selected based on physical characteristics of ingredients and desired product profile.
The compression operation may be monitored in terms of tablet weight, compression force, hardness, thickness and machine speed. Variability in such parameters can be used to control uniformity of products.
A pharmaceutical-quality control system is implemented through all stages of the manufacturing process. Calcium citrate 1000 mg + vitamin D3 200 IU + zinc 4 mg + magnesium 100 mg tablets are subjected to physical, chemical and performance tests based on an established quality management plan.
Typical quality attributes tested will include appearance, average weight, weight variation, hardness, friability, disintegration, dissolution and uniformity of dosage. Validated analytical methods can be used to assess the specified mineral and vitamin components.
Relatively low concentrations of vitamin D3 require special sampling protocols in order to demonstrate uniformity. Mineral components will be tested using validated analytical approaches.
In-line quality assurance tests can be used to monitor blend uniformity, tablet weight, hardness, thickness and appearance. Such quality checks can be used to troubleshoot manufacturing problems before the entire batch reaches out through further performance tests.
Appropriate laboratory documentation, test records, batching and release procedures will help facilitate quality control.
Stability testing for a multi-product vitamin-mineral combination can reveal how a finished product responds to controlled environmental conditions. Such studies reveal potential changes in appearance, assay values, dissolution, disintegration and overall physical characteristics.
Appropriate packaging can be selected based on the stability characteristics of the product. Optional packaging options may include pharmaceutical-grade strips, blister packs, bottles or sachets. Each type of packaging will be selected to protect the product against moisture, light, contamination and physical damage.
Finished-product packaging will include clear and compliant product information in accordance with relevant regulatory guidance regarding composition, potency, batch details, manufacturing, expiry, pack size and labeling requirements. Packaging design can contribute to a professional portfolio presentation.
A multi-nutrient formulation that comprises calcium citrate 1000 mg, vitamin D3 200 IU, zinc 4 mg and magnesium 100 mg can be incorporated into a diversified portfolio where a broad selection of vitamin, mineral and nutritional combinations are marketed to the same or different customer segments.
Careful development practices are essential to ensure each of the four main ingredients remains within acceptable limits through each manufacturing stage. As part of a professional pharmaceutical product range, this formulation can support the development of a PCD Pharma Franchise portfolio through access to professional quality, reliable sourcing, rigorous manufacturing and thorough analytical methods.
All stages from raw ingredient testing, through weighing, blending, compression and packaging will follow established protocols. Variations in process parameters can be identified and addressed to ensure the uniformity and high quality of each finished product.
This combination formulation – calcium citrate 1000 mg, vitamin D3 200 IU, zinc 4 mg and magnesium 100 mg – can be produced with a focus on integrity, quality, stability and a healthy professional presentation.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech